source
- Entrada stock falls on Duchenne data; Wegovy expands accessPlus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...Endpoints · 2mo ago↗ source
- STAT+: More political interference at the FDA?A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newsletter.STAT · 2mo ago↗ source
- Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in GermanyPlus, news about FDA's one-day inspections and BioMADE: 🇵🇷 Amgen pours another $300M into Puerto Rico: The funds will be used to bolster its biologics production in Juncos, which was established ...Endpoints · 2mo ago